Skip to content
    OTLK stock page

    Outlook Therapeutics, Inc.

    OTLK · earnings call history

    1 call analysed
    1. Jun 2026Q3 FY26Aug 14, 2026

      Outlook Therapeutics Q3 FY26 — FDA Approval of LYTENAVA and U.S. Commercial Launch Preparations

      Read the brief

    Browse all US companies on the earnings-call register.